Zhejiang Cheng Yi Pharmaceutical Co Ltd (SHG:603811) — Market Cap & Net Worth
Market Cap & Net Worth: Zhejiang Cheng Yi Pharmaceutical Co Ltd (603811)
Zhejiang Cheng Yi Pharmaceutical Co Ltd (SHG:603811) has a market capitalization of $483.45 Million (CN¥3.30 Billion) as of August 7, 2026. Listed on the SHG stock exchange, this China-based company holds position #12374 globally and #3597 in its home market, demonstrating a 1.12% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Cheng Yi Pharmaceutical Co Ltd's stock price CN¥7.21 by its total outstanding shares 458226048 (458.23 Million). See 603811 capex reinvestment rate to understand how much of operating cash flow is reinvested back into capital assets.
Zhejiang Cheng Yi Pharmaceutical Co Ltd Market Cap History: 2017 to 2026
Zhejiang Cheng Yi Pharmaceutical Co Ltd's market capitalization history from 2017 to 2026. Data shows growth from $466.44 Million to $483.45 Million (3.45% CAGR).
Zhejiang Cheng Yi Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Cheng Yi Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.87x
Zhejiang Cheng Yi Pharmaceutical Co Ltd's market cap is 0.87 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.61x
Zhejiang Cheng Yi Pharmaceutical Co Ltd's market cap is 3.61 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $466.44 Million | $340.89 Million | $69.24 Million | 1.37x | 6.74x |
| 2018 | $360.84 Million | $545.77 Million | $96.91 Million | 0.66x | 3.72x |
| 2019 | $581.74 Million | $681.23 Million | $131.39 Million | 0.85x | 4.43x |
| 2020 | $745.72 Million | $758.13 Million | $165.14 Million | 0.98x | 4.52x |
| 2021 | $747.97 Million | $693.96 Million | $170.80 Million | 1.08x | 4.38x |
| 2022 | $657.04 Million | $654.97 Million | $161.58 Million | 1.00x | 4.07x |
| 2023 | $695.34 Million | $671.63 Million | $162.90 Million | 1.04x | 4.27x |
| 2024 | $517.65 Million | $714.37 Million | $200.70 Million | 0.72x | 2.58x |
| 2025 | $704.06 Million | $812.35 Million | $195.12 Million | 0.87x | 3.61x |
Competitor Companies of 603811 by Market Capitalization
Companies near Zhejiang Cheng Yi Pharmaceutical Co Ltd in the global market cap rankings as of August 7, 2026.
Key companies related to Zhejiang Cheng Yi Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #505 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #554 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #556 globally with a market cap of $48.64 Billion USD ( CN¥332.41 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #625 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #505 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #554 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.91 |
| #556 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $48.64 Billion | CN¥52.11 |
| #625 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.80 |
Zhejiang Cheng Yi Pharmaceutical Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Zhejiang Cheng Yi Pharmaceutical Co Ltd's market cap moved from $466.44 Million to $ 483.45 Million, with a yearly change of 3.45%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥483.45 Million | -31.33% |
| 2025 | CN¥704.06 Million | +36.01% |
| 2024 | CN¥517.65 Million | -25.55% |
| 2023 | CN¥695.34 Million | +5.83% |
| 2022 | CN¥657.04 Million | -12.16% |
| 2021 | CN¥747.97 Million | +0.30% |
| 2020 | CN¥745.72 Million | +28.19% |
| 2019 | CN¥581.74 Million | +61.22% |
| 2018 | CN¥360.84 Million | -22.64% |
| 2017 | CN¥466.44 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 7th, 2026 the market cap of Zhejiang Cheng Yi Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $483.45 Million USD |
| MoneyControl | $483.45 Million USD |
| MarketWatch | $483.45 Million USD |
| marketcap.company | $483.45 Million USD |
| Reuters | $483.45 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Cheng Yi Pharmaceutical Co Ltd
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. engages in the research, development, production, and sales of formulations and active pharmaceutical ingredients in China and internationally. The company offers glucosamine hydrochloride raw materials and preparations, gastrodin raw materials, ribavirin preparations raw materials, and sulfur dioxide raw materials. It also provides injections, food, cap… Read more